Mr. Beery has served as a director since April 2004. Mr. Beery has served since March 2002 as Senior Of Counsel in the London office of Covington & Burling, an international law firm based in Washington, D.C. Prior to his retirement in June 2001, Mr. Beery served as Senior Vice President and General Counsel of GlaxoSmithKline PLC, a UK-based global pharmaceutical company. From 1993 until the formation of the merged company GlaxoSmithKline in December 2000, Mr. Beery served as Senior Vice President, General Counsel and Secretary of SmithKline Beecham PLC. Mr. Beery holds a BA from Harvard College and a JD from Stanford Law School. He is currently a director of deCode genetics, Inc., Orchid Biosciences, Inc., the Theodora Children's Trust and the London Centre for the International Education of Students, and is a member of the Advisory Board of the Stanford Law School Program in Law, Science and Technology.
Mr. Devine retired from public accounting in 2003 after a successful 24-year career primarily spent as a partner with Arthur Andersen LLP and later with Deloitte & Touche LLP. During his years at Arthur Andersen, Mr. Devine served in many technical leadership capacities including being a member of the firm's worldwide technology industries technical consultation group and being the southeastern United States technical coordinator for the software industry. After his retirement from public accounting, Mr. Devine served from 2004 to 2007 as the chief financial officer of Secure Software, Inc., a software developer.
Mr. Devine holds a master of business administration degree from Penn State University and a bachelor of arts degree from Rider College.
Mr. Flanagan is Executive Vice President of Clark Enterprises, Inc. ("Clark"), one of the largest privately-held construction companies in the country. Prior to joining Clark, Mr. Flanagan was Treasurer, Secretary and member of the Board of Directors of the Baltimore Orioles, Inc. and was also employed as a member of Arthur Andersen's audit division in the Washington, D. C. office. Certified as a public accountant in Washington, D. C., Mr. Flanagan received a bachelor's degree in business administration from Georgetown University and a master's degree in taxation from the American University School of Business. Mr. Flanagan has been a Director of Martek since April 2002 and in June of 2007 was elected Chairman of Martek's Board of Directors.
Mrs. Kawalek retired in 2004 after serving for 25 years in various capacities at Quaker Oats, Inc., a consumer goods company and, since 2001, a business unit of PepsiCo. From 2002 until her retirement, she served as President of PepsiCo's Quaker Foods division. In 2001, Mrs. Kawalek served as President of Quaker Oats' U.S. Foods division and from 1997 through 2000, she served as President of the Hot Breakfast division. Mrs. Kawalek also serves as director for Kimball International, Inc. Mrs. Kawalek has been a director of Martek since January 2006.
Mr. Keller became a Director of Martek following his retirement as Senior Vice President of Sales and Marketing at the end of fiscal year 2005. Mr. Keller served as Martek's Senior Vice President of Sales and Marketing from September 1997 to October 2005. Prior to joining Martek, Mr. Keller had been consulting after spending a 25-year career at Merck, most recently as Vice President of Sales from 1986 to 1993. In this position, he was responsible for all U.S. sales operations, including the direction of a support staff of 4,500 personnel and a sales volume of $4.2 billion. Some of the products introduced under Mr. Keller included Pepcid, Mefoxin, Primaxin, Vasotec, Mevocor, Zocor, Proscor and Prilosec. Mr. Keller has a M.S. degree from the University of Pittsburgh and a B.S. degree from Duquesne University.
Mr. MacMaster served in various management positions at Merck & Co., Inc. ("Merck") from 1961 to 1988, at which time he was appointed Senior Vice President responsible for ten divisions, including Manufacturing and Technology and Pharmaceutical Manufacturing. Mr. MacMaster retired from Merck in 1991 and currently serves as a Director for Neose Technologies, Inc. (biotechnology) and Stratton Mutual Funds. Mr. MacMaster has been a Director of Martek since 1993.
Since 1990, Mr. Rotberg has been an independent advisor to international development and financial institutions. From 1987 to 1990, Mr. Rotberg was Executive Vice President and a member of the Executive Committee at Merrill Lynch & Co., Inc. From 1969 to 1987, Mr. Rotberg was Vice President and Treasurer of the World Bank. Mr. Rotberg has been a Director of Martek since 1992.
Mr. Steve Dubin was appointed Chief Executive Officer in July 2006. He joined the Company in April 1992, holding a variety of positions including Chief Financial Officer, Treasurer, Secretary & General Counsel, and Senior Vice President of Business Development. In 2003, Mr. Dubin was appointed President of the Company. In these capacities, he was responsible for the Company's strategic planning, operations, finance, and sales and marketing groups. Prior to joining the Company, Mr. Dubin was employed in various positions at Suburban Bank (now a part of Bank of America) including Vice President of Suburban Capital Corporation, the bank's venture capital subsidiary. In this position, he helped lead Martek's initial round of institutional venture financing in 1986.
Mr. Dubin currently serves in a variety of non-profit business leadership positions including the Tech Council of Maryland and MdBio, a private non-profit corporation that seeks to unify, empower and advance Maryland's bioscience industry. Mr. Dubin holds a Bachelors degree from University of Maryland, College Park, and a Juris Doctor degree from the National Law Center at the George Washington University in Washington, D.C. He is a licensed CPA and a member of the Maryland Bar.
Mr. D'Andrea is a co-founder and partner at Valhalla Partners, a Virginia- based venture capital firm that manages greater than $440 million in capital and invests primarily in technology companies. Mr. D'Andrea brings an extensive business background to Martek's Board having served as chief financial officer for Yurie Systems, Inc., which was acquired by Lucent Technology in 1998, and several other technology companies over the past twenty years. Mr. D'Andrea also previously held a variety of positions with and gained valuable international business experience working at Marriott Corporation and Xerox Corporation.
Mr. D'Andrea holds a Masters in Business Administration from Drexel University and a Bachelor of Arts degree in Foreign Service and International Politics from The Pennsylvania State University. He is active in the greater Baltimore/Washington, D.C. area business community and has served in a variety of capacities for the Tech Council of Maryland and the University of Maryland's Technology Advancement Program.
Mr. Mayer brings an extensive domestic and international business background to Martek's board having served from 1981 to 2007 in a variety of executive capacities for Danisco A/S, one of the world's leading producers of ingredients for food and other consumer products. In his most recent executive role, Mr. Mayer served as chief executive officer and chairman of the board for Genencor International, Inc., a wholly-owned subsidiary of Danisco A/S specializing in the development and manufacture of industrial enzymes.
Mr. Mayer holds a doctorate in chemical engineering from the Massachusetts Institute of Technology and a bachelor of science degree in chemical engineering from Columbia University. He also currently serves on the board of directors of Kalsec, Inc., a privately-held food additive company.
Mr. Pernock has been Chairman of the Board of Fibrocell
Science, Inc., a biotech dermatology company, since September 2009 and became Chief Executive Officer in
February 2010. Previously, Mr. Pernock served in a variety of executive capacities for GSK from 1994 to 2009, including most recently as Senior Vice President of Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions of GSK's U.S. operations. Prior to his appointment as Senior Vice President, Mr. Pernock had served as Vice President of Marketing—Pharmaceuticals, Vice President of Sales and Marketing—Oncology, Vice President, Managed Care, and Vice President, Sales. Mr. Pernock has been a director of Martek since September 2009.
= Chair of the Board
= Chair
= Member
= Independent Director
